DaVita Inc. $DVA Shares Sold by Gotham Asset Management LLC

Key Points

• Gotham Asset Management LLC reduced its holdings in DaVita Inc. by 19.5%, selling 25,566 shares, and now owns approximately 0.14% of the company valued at $16.18 million.
• DaVita reported $2.95 EPS exceeding analysts' expectations during its latest earnings call, alongside a 6.1% revenue increase year-over-year.
• Several institutional investors have recently modified their positions in DaVita, with institutional ownership now at 90.12% of the company's stock.

Gotham Asset Management LLC cut its stake in DaVita Inc. (NYSE:DVA - Free Report) by 19.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,779 shares of the company's stock after selling 25,566 shares during the quarter. Gotham Asset Management LLC owned approximately 0.14% of DaVita worth $16,181,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. lifted its stake in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after buying an additional 76 shares in the last quarter. Copia Wealth Management acquired a new position in DaVita during the fourth quarter worth about $30,000. National Pension Service boosted its position in DaVita by 74.3% during the first quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after acquiring an additional 84 shares during the last quarter. Y.D. More Investments Ltd acquired a new position in DaVita during the first quarter worth about $35,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new position in DaVita during the first quarter worth about $83,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Trading Up 1.7%

NYSE:DVA traded up $2.22 on Tuesday, hitting $136.73. The stock had a trading volume of 714,980 shares, compared to its average volume of 853,529. The company has a quick ratio of 1.34, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. The stock has a market cap of $9.78 billion, a price-to-earnings ratio of 13.44, a PEG ratio of 0.99 and a beta of 1.13. The company has a fifty day moving average price of $139.24 and a two-hundred day moving average price of $141.76. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.70 by $0.25. The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. DaVita's revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, August 22nd. Barclays lowered their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $164.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.